Forbion

Forbion, a venture capital firm based in the Netherlands, specializes in investing in life sciences companies. Founded in 2006, Forbion focuses on drug development, medical devices, and diagnostics, addressing high medical needs. The firm has raised significant funds, including €190 million for its FCF I Co-Invest Fund and FCF II, targeting private companies primarily in Europe, with additional investments in North America and Israel. Forbion's notable portfolio companies include Replimune, a leader in oncolytic immunotherapies, and Gyroscope Therapeutics, which was acquired by Novartis. The firm has a strong track record with successful exits, such as the sale of Fovea Pharmaceuticals to Sanofi-Aventis and the acquisition of PanGenetics by Abbott. The firm is led by Managing Partner Bart Bergstein and has expanded its European presence with offices in Naarden and Munich. Forbion's investment strategy focuses on creating value through active involvement and leading investment syndicates in the life sciences sector.